StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

Adaptive Biotechnologies r&d expenses

Research and development expenses are spending on new products and technology.

Adaptive Biotechnologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.21M, down 7.8% year over year. For fiscal 2025 it was $93.77M, down 8.9% from the year before. The highest annual figure on record is $142.34M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.77M-8.9%
FY2024Dec 31, 2024$102.95M-15.7%
FY2023Dec 31, 2023$122.12M-13.9%
FY2022Dec 31, 2022$141.76M-0.4%
FY2021Dec 31, 2021$142.34M+22.6%
FY2020Dec 31, 2020$116.07M+64.2%
FY2019Dec 31, 2019$70.71M+80.6%
FY2018Dec 31, 2018$39.16M+22.4%
FY2017Dec 31, 2017$32.00M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.15M-20.6%
Q1 FY2026Mar 31, 2026$23.62M-2.4%
Q4 FY2025Dec 31, 2025$21.76M-6.2%
Q3 FY2025Sep 30, 2025$23.67M-2.0%
Q2 FY2025Jun 30, 2025$24.13M-4.8%
Q1 FY2025Mar 31, 2025$24.20M-20.0%
Q4 FY2024Dec 31, 2024$23.19M-19.3%
Q3 FY2024Sep 30, 2024$24.16M-15.3%
Q2 FY2024Jun 30, 2024$25.35M-21.4%
Q1 FY2024Mar 31, 2024$30.25M-7.2%
Q4 FY2023Dec 31, 2023$28.75M-7.9%
Q3 FY2023Sep 30, 2023$28.53M-20.0%
Q2 FY2023Jun 30, 2023$32.24M-13.0%
Q1 FY2023Mar 31, 2023$32.60M-13.8%
Q4 FY2022Dec 31, 2022$31.22M-10.0%
Q3 FY2022Sep 30, 2022$35.66M-1.1%
Q2 FY2022Jun 30, 2022$37.04M-2.0%
Q1 FY2022Mar 31, 2022$37.84M+12.0%
Q4 FY2021Dec 31, 2021$34.70M-3.2%
Q3 FY2021Sep 30, 2021$36.07M+19.0%
Q2 FY2021Jun 30, 2021$37.80M+45.4%
Q1 FY2021Mar 31, 2021$33.77M+41.1%
Q4 FY2020Dec 31, 2020$35.83M+69.1%
Q3 FY2020Sep 30, 2020$30.31M+47.8%
Q2 FY2020Jun 30, 2020$25.99M+57.3%
Q1 FY2020Mar 31, 2020$23.94M+91.7%
Q4 FY2019Dec 31, 2019$21.19M+91.5%
Q3 FY2019Sep 30, 2019$20.51M+109.6%
Q2 FY2019Jun 30, 2019$16.53M+74.9%
Q1 FY2019Mar 31, 2019$12.48M–
Q4 FY2018Dec 31, 2018$11.07M–
Q3 FY2018Sep 30, 2018$9.78M–
Q2 FY2018Jun 30, 2018$9.45M–

More Adaptive Biotechnologies figures

See a number that looks wrong?